Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology